Fosamax Judge Restricts Bellwether Trial Evidence

Law360, New York (November 3, 2010, 1:22 PM EDT) -- The judge hearing one of the bellwether cases in multidistrict litigation alleging the osteoporosis drug Fosamax caused a bone-rotting condition in the plaintiff’s jaw has elected to bar the plaintiff from introducing evidence of Merck & Co.'s conduct after March 31, 2003.

Judge John F. Keenan in the U.S. District Court for the Southern District of New York on Oct. 27 also said he would exclude expert testimony from one doctor and evidence concerning risks of Fosamax use other than osteonecrosis of the jaw.

He denied...
To view the full article, register now.




Case Information

Case Title

Graves v. Merck & Co., Inc.

Case Number



New York Southern

Nature of Suit

Personal Inj. Prod. Liability


John F. Keenan

Date Filed

July 21, 2006

Law Firms


UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.